Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

The third quarter marked an important transition for Skye as a metabolic-focused company with the launch of our Phase 2 obesity clinical trial for nimacimab. We believe our truly ...

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report) shares were up 5.3% during trading on Wednesday .The company traded as high as $5.20 and last traded at $5.20. Approximately 168,072 shares ...

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...

Skye Bioscience ( (SKYE)) just unveiled an announcement. Skye Bioscience, Inc. held a special meeting where stockholders approved an amendment to increase the shares available under the 2014 ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical ...

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic ...